Editorial: Inhibition of lipoprotein-associated phospholipase activity by darapladib shifting gears in cardiovascular drug development: are antiinflammatory drugs the next frontier?

Circulation

Volumn 118, Issue 11, 2008, Pages 1120-1122

  Boekholdt, Matthijs S ^a,b   De Winter, Robbert J ^b   Kastelein, John J P ^a  

^a Department of Vascular Medicine ^*  (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Atherosclerosis; Drugs; Editorials; Inflammation; Lipids

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ATORVASTATIN; C REACTIVE PROTEIN; DARAPLADIB; GELATINASE B; INTERLEUKIN 6; MYELOPEROXIDASE; PLACEBO; ANTIINFLAMMATORY AGENT; BENZALDEHYDE DERIVATIVE; CARDIOVASCULAR AGENT; ENZYME INHIBITOR; OXIME;

CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG EFFICACY; EDITORIAL; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; INTRAVASCULAR ULTRASOUND; ISCHEMIC HEART DISEASE; NONHUMAN; PRIORITY JOURNAL; RISK REDUCTION; CORONARY ARTERY DISEASE; DRUG ANTAGONISM; PATHOLOGY;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANTI-INFLAMMATORY AGENTS; BENZALDEHYDES; CARDIOVASCULAR AGENTS; CORONARY DISEASE; ENZYME INHIBITORS; HUMANS; OXIMES;

EID: 54049108847     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.108.795195     Document Type: Editorial

References (22)

1. Laatikainen T, Critchley J, Vartiainen E, Salomaa V, Ketonen M, Capewell S. Explaining the decline in coronary heart disease mortality in Finland between 1982 and 1997. Am J Epidemiol. 2005;162:764-773.
2. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
3. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC,Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435.
4. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a mul- tifactorial intervention on mortality in type 2 diabetes. N Engl J Med.2008;358:580-591.
5. Tardif JC, Gregoire J, Schwartz L, Title L, Laramee L, Reeves F, Lesperance J, Bourassa MG, L'Allier PL, Glass M, Lambert J, Guertin MC, for the Canadian Antioxidant Restenosis Trial (CART-1) Investigators. Effects of AGI-1067 and probucol after percutaneous coronary interventions. Circulation. 2003;107:552-558.
6. Tardif JC, McMurray JJ, Klug E, Small R, Schumi J, Choi J, Cooper J,Scott R, Lewis EF, L'Allier PL, Pfeffer MA, for the Aggressive Reduction of Inflammation Stops Events (ARISE) Trial Investigators. Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;371:1761-1768.
7. Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis. Arterioscler Thromb Vasc Biol. 2005;25:923-931.
8. Kolodgie FD, Burke AP, Skorija KS, Ladich E, Kutys R, Makuria AT,Virmani R. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. ArteriosclerThromb Vasc Biol. 2006;26:2523-2529.
9. Carpenter KL, Dennis IF, Challis IR, Osborn DP, Macphee CH, Leake DS, Arends MJ, Mitchinson MJ. Inhibition of lipoprotein-associated phospholipase A2 diminishes the death-inducing effects of oxidised LDL on human monocyte-macrophages. FEBS Lett. 2001;505:357-363.
10. Quarck R, De Geest B, Stengel D, Mertens A, Lox M, Theilmeier G,Michiels C, Raes M, Bult H, Collen D, Van Veldhoven P, Ninio E, Holvoet P. Adenovirus-mediated gene transfer of human platelet- activating factor-acetylhydrolase prevents injury-induced neointima for-mation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2001;103:2495-2500.
11. Tsimikas S, Tsironis LD, Tselepis AD. New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease. Arterioscler Thromb Vasc Biol.2007;27:2094-2099.
12. Chen CH. Platelet-activating factor acetylhydrolase: is it good or bad for you? Curr Opin Lipidol. 2004;15:337-341.
13. Packard CJ, O'Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J, Macphee CH, Suckling KE, Krishna M, Wilkinson FE, Rumley A, Lowe GD. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. N Engl J Med. 2000;343:1148-1155.
14. Koenig W, Twardella D, Brenner H, Rothenbacher D. Lipoprotein- associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol. 2006;26:1586-1593.
15. O'Donoghue M, Morrow DA, Sabatine MS, Murphy SA, McCabe CH, Cannon CP, Braunwald E. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (Pravastatin or Atorva- statin Evaluation and Infection Therapy-Thrombolysis In MyocardialInfarction) trial. Circulation. 2006;113:1745-1752.
16. Mohler ER, Ballantyne CM, Davidson MH, Hanefeld M, Ruilope LM, Johnson JL, Zalewski A, for the Darapladib Investigators. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multi- center, randomized, double-blind, placebo-controlled study. J Am CollCardiol. 2008;51:1632-1641.
17. Serruys PW, Garcia-Garcia HM, Buszman P, Erne P, Verheye S, Aschermann M, Duckers H, Bleie O, Dudek D, B0tker HE, von Birgelen C, D'Amico D, Hutchinson T, Zambanini A, Mastik F, van Es G-A, van der Steen AFW, Vince DG, Ganz P, Hamm CW, Wijns W, Zalewski A, for the Integrated Biomarker and Imaging Study-2 Investigators. Effects of the direct lipoprotein-associated phospholipase A2 inhibitor darapladib on human coronary atherosclerotic plaque. Circulation. 2008;118:1172-1182.
18. de Korte CL, Pasterkamp G, van der Steen AF, Woutman HA, Born N. Characterization of plaque components with intravascular ultrasound elastography in human femoral and coronary arteries in vitro. Circulation.2000;102: 617-623.
19. Diethrich EB, Pauliina Margolis M, Reid DB, Burke A, Ramaiah V, Rodriguez-Lopez JA, Wheatley G, Olsen D, Virmani R. Virtual histology intravascular ultrasound assessment of carotid artery disease: the Carotid Artery Plaque Virtual Histology Evaluation (CAPITAL) study.J Endovasc Ther. 2007;14:676-686.
20. Nasu K, Tsuchikane E, Katoh O, Vince DG, Virmani R, Surmely JF, Murata A, Takeda Y, Ito T, Ehara M, Matsubara T, Terashima M, Suzuki T. Accuracy of in vivo coronary plaque morphology assessment: a validation study of in vivo virtual histology compared with in vitro histopa-thology. J Am Coll Cardiol. 2006;47:2405-2412.
21. Hong MK, Mintz GS, Lee CW, Suh J, Kim JH, Park DW, Lee SW, Kim YH, Cheong SS, Kim JJ, Park SW, Park SJ. Comparison of virtual histology to intravascular ultrasound of culprit coronary lesions in acute coronary syndrome and target coronary lesions in stable angina pectoris. Am J Cardiol. 2007;100:953-959.
22. Surmely JF, Nasu K, Fujita H, Terashima M, Matsubara T, Tsuchikane E, Ehara M, Kinoshita Y, Zheng QX, Tanaka N, Katoh O, Suzuki T. Coronary plaque composition of culprit/target lesions according to the clinical presentation: a virtual histology intravascular ultrasound analysis.Eur Heart J. 2006;27:2939-2944.